http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2018513843-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-70 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-62 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-622 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-62 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09 |
| filingDate | 2016-03-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2018-05-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2018513843-A |
| titleOfInvention | Insulin analogues containing glucose-controlled conformational switches |
| abstract | SOLUTION: A two-chain insulin analogue has (i) an A chain modified with a monomeric glucose binding element at or near its N-terminus, and (ii) this bond can be replaced by glucose. It includes a B chain modified at or near its C-terminus by an element reversibly linked to a monomeric glucose binding element. The monomeric glucose binding element may be a (selectively halogenated) phenylboronic acid derivative. The B chain may be modified with a diol-containing element derived from a monosaccharide, disaccharide, or oligosaccharide, a non-saccharide diol-containing structure, or an α-hydroxycarboxylic acid-containing structure. The analog can be prepared by trypsin-mediated semi-synthesis. The formulation is dissolved in a soluble solution at pH 7.0-8.0 in the presence or absence of zinc ions at a molar ratio of 0.0-3.0 per insulin analog monomer, U-10-U The strength can be -1000. A diabetic patient can be administered a physiologically effective amount of the insulin analog subcutaneously, intraperitoneally, or orally. [Selection] Figure 3A |
| priorityDate | 2015-03-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 462.